Filter by: patients
Home > Community Treatment Reports and Side Effects > Mecasermin Treatment Report
What is Mecasermin?

Mecasermin is manufactured as a treatment for 'short stature' due to severe primary IGF-1 deficiency (Primary IGFD). Mecasermin is also known as rhIGF-1

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
ALS (Amyotrophic Lateral Sclerosis) 4 1 Efficacy_slight
Other 1 0

See all 3 patients currently taking Mecasermin

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
 0
Moderate
 1
Mild
 0
None
 0

Reported Dosages

  7.2 mg daily 20 mg daily 36 mg/0.6 mL daily 200 daily
  1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1  

Reported Stop Reasons

Why Patients Stopped Taking Mecasermin (multiple reasons could be selected)
Reason # Patients Percentage of patients
Did not seem to work 1   Did not seem to work: 100%
Side effects too severe 1   Side effects too severe: 100%

See all 1 patient who’ve stopped taking Mecasermin

Reported Duration See details about how long patients take this treatment ▼

Stopped Taking Mecasermin

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of Mecasermin

Always
 1 100%
Usually
 0 0%
Sometimes
 0 0%
Never
 0 0%

Burden

Difficulty being on treatment

Burden of Mecasermin

Very
 0 0%
Somewhat
 0 0%
A little
 1 100%
Not at all
 0 0%

Cost

Paid out of pocket

Cost of Mecasermin

$200+
 1 100%
$100-199
 0 0%
$50-99
 0 0%
$25-49
 0 0%
< $25
 0 0%

See more information, including instructions, precautions, side effects, and interactions.

Report created on May 28, 2012.